Investigating Potential Securities Fraud: Sensus Healthcare, Inc. Under Scrutiny

Investor Alert: Investigation into Sensus Healthcare, Inc.

On September 23, 2025, Pomerantz LLP publicly announced its investigation into Sensus Healthcare, Inc. (NASDAQ: SRTS) and its financial practices, particularly focusing on possible securities fraud. Investors holding Sensus shares are encouraged to consult with the law firm, especially in light of recent underwhelming financial disclosures from the company.

Financial Performance and Concerns

The turning point for this investigation was Sensus’ financial report released on August 7, 2025, which indicated a GAAP earnings-per-share figure of -$0.06 that fell short of analysts’ forecasts by $0.09. Additionally, Sensus reported revenue figures totaling $7.3 million, marking a substantial 20.7% decline year-over-year and missing estimates by around $2 million. The company attributed these disappointing numbers primarily to a decreased quantity of units sold to a significant client, although there was some offset from increased recurring revenue from Fair Deal Agreements.

Following the announcement, Sensus shares took a sharp dip, falling $1.89 or 35.32%, leading to a closing price of $3.46 on August 8, 2025. This significant loss of shareholder value has prompted Pomerantz LLP to assess whether the decline stems from any illicit actions or misrepresentations by the company and its executives.

Nature of the Investigation

Pomerantz LLP is recognized as one of the most reputable law firms specializing in corporate, securities, and antitrust class litigations. With a legacy dating back over 85 years since the firm was founded by the esteemed Abraham L. Pomerantz—often referred to as the dean of the class action bar—the firm has continually championed the rights of investors and victims of corporate wrongdoing.

The firm's current focus on Sensus Healthcare highlights the ongoing need for vigilance in the financial markets, particularly when companies face significant downturns. Investigations such as this not only serve to protect investor interests but also uphold accountability within corporate frameworks.

Next Steps for Investors

Shareholders and potential investors of Sensus Healthcare who believe they may have been affected by these events should promptly reach out to the legal team at Pomerantz LLP. Interested parties can contact Danielle Peyton via email at [email protected] or by phone at 646-581-9980, extension 7980, to learn more about their rights and potential involvement in any class action related to this matter.

Furthermore, there exists an opportunity for affected investors to join the class action, providing them a collective voice in addressing the alleged mismanagement and misconduct that may have occurred within the company.

Conclusion

As the landscape for public companies continues to evolve, investigations like the one initiated by Pomerantz LLP serve as a reminder for investors to remain informed and proactive in their investments. The firm remains dedicated to fighting against securities fraud, breaches of fiduciary duties, and corporate misconduct, ensuring that investors' rights are upheld across the board.

For more updates on such investigations and to understand more about your rights as an investor, keep an eye on the latest news from renowned law firms setting precedents in bringing justice to affected stakeholders.